rhughes6	10.18632/oncotarget.21545	<http://dx.doi.org/10.18632/oncotarget.21545>; rel="canonical", <http://www.oncotarget.com/fulltext/21545>; version="vor"; rel="item"	<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:j.0="http://purl.org/dc/terms/" xmlns:j.1="http://prismstandard.org/namespaces/basic/2.1/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:j.2="http://purl.org/ontology/bibo/" xmlns:j.3="http://xmlns.com/foaf/0.1/"><rdf:Description rdf:about="http://dx.doi.org/10.18632/oncotarget.21545"><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/amy-l-lane-4rhc2n2gt87s"><j.3:name>Amy L. Lane</j.3:name><j.3:familyName>Lane</j.3:familyName><j.3:givenName>Amy L.</j.3:givenName></j.3:Person></j.0:creator><j.2:doi>10.18632/oncotarget.21545</j.2:doi><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/jiang-wen-4rhc2n2gt87s"><j.3:name>Jiang Wen</j.3:name><j.3:familyName>Wen</j.3:familyName><j.3:givenName>Jiang</j.3:givenName></j.3:Person></j.0:creator><j.0:publisher>Impact Journals, LLC</j.0:publisher><owl:sameAs rdf:resource="doi:10.18632/oncotarget.21545"/><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/yon-son-betty-kim-4rhc2n2gt87s"><j.3:name>Yon Son Betty Kim</j.3:name><j.3:familyName>Kim</j.3:familyName><j.3:givenName>Yon Son Betty</j.3:givenName></j.3:Person></j.0:creator><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/han-w-tun-4rhc2n2gt87s"><j.3:name>Han W. Tun</j.3:name><j.3:familyName>Tun</j.3:familyName><j.3:givenName>Han W.</j.3:givenName></j.3:Person></j.0:creator><j.0:isPartOf><j.2:Journal rdf:about="http://id.crossref.org/issn/1949-2553"><owl:sameAs>urn:issn:1949-2553</owl:sameAs><j.0:title>Oncotarget</j.0:title><j.1:issn>1949-2553</j.1:issn><j.2:issn>1949-2553</j.2:issn></j.2:Journal></j.0:isPartOf><owl:sameAs rdf:resource="info:doi/10.18632/oncotarget.21545"/><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/lori-hazlehurst-4rhc2n2gt87s"><j.3:name>Lori Hazlehurst</j.3:name><j.3:familyName>Hazlehurst</j.3:familyName><j.3:givenName>Lori</j.3:givenName></j.3:Person></j.0:creator><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/laura-marlow-4rhc2n2gt87s"><j.3:name>Laura Marlow</j.3:name><j.3:familyName>Marlow</j.3:familyName><j.3:givenName>Laura</j.3:givenName></j.3:Person></j.0:creator><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/robert-hughes-4rhc2n2gt87s"><j.3:name>Robert Hughes</j.3:name><j.3:familyName>Hughes</j.3:familyName><j.3:givenName>Robert</j.3:givenName></j.3:Person></j.0:creator><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/anthony-b-pinkerton-4rhc2n2gt87s"><j.3:name>Anthony B. Pinkerton</j.3:name><j.3:familyName>Pinkerton</j.3:familyName><j.3:givenName>Anthony B.</j.3:givenName></j.3:Person></j.0:creator><j.0:identifier>10.18632/oncotarget.21545</j.0:identifier><j.1:doi>10.18632/oncotarget.21545</j.1:doi><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/christina-a-von-roemeling-4rhc2n2gt87s"><j.3:name>Christina A. von Roemeling</j.3:name><j.3:familyName>von Roemeling</j.3:familyName><j.3:givenName>Christina A.</j.3:givenName></j.3:Person></j.0:creator><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/derek-c-radisky-4rhc2n2gt87s"><j.3:name>Derek C. Radisky</j.3:name><j.3:familyName>Radisky</j.3:familyName><j.3:givenName>Derek C.</j.3:givenName></j.3:Person></j.0:creator><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/james-l-miller-4rhc2n2gt87s"><j.3:name>James L. Miller</j.3:name><j.3:familyName>Miller</j.3:familyName><j.3:givenName>James L.</j.3:givenName></j.3:Person></j.0:creator><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/thomas-r-caulfield-4rhc2n2gt87s"><j.3:name>Thomas R. Caulfield</j.3:name><j.3:familyName>Caulfield</j.3:familyName><j.3:givenName>Thomas R.</j.3:givenName></j.3:Person></j.0:creator><j.0:title>Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy</j.0:title><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/ilah-bok-4rhc2n2gt87s"><j.3:name>Ilah Bok</j.3:name><j.3:familyName>Bok</j.3:familyName><j.3:givenName>Ilah</j.3:givenName></j.3:Person></j.0:creator><j.0:date rdf:datatype="http://www.w3.org/2001/XMLSchema#date" >2017-10-06</j.0:date><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/john-a-copland-4rhc2n2gt87s"><j.3:name>John A. Copland</j.3:name><j.3:familyName>Copland</j.3:familyName><j.3:givenName>John A.</j.3:givenName></j.3:Person></j.0:creator><j.2:volume>9</j.2:volume><j.1:volume>9</j.1:volume></rdf:Description></rdf:RDF>
